At the J.P. Morgan Healthcare Conference, Moderna (MRNA) announced several financial updates on its business and updates on its pipeline progress.Moderna’s Financial Updates Fail to Impress InvestorsFor 2024Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$ ...

Key TakeawaysModerna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two-month pennant pattern, setting the stage for a potential continuation move lower.Investors should watch crucial support levels on Moderna's chart around $30 and $13, while also monitoring key resistance levels near $57 and $68. Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plungin ...

Key TakeawaysThe S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave of earnings reports from the nation's biggest banks.Moderna shares plummeted after the biotech firm slashed its 2025 revenue guidance, citing uncertain vaccine demand.Shares of managed care companies moved higher following the U.S. government's proposal to raise Medicare Advantage reimbursement rates next year. Major U.S. equities indexes were mixed to start a new trading week ahead of ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Key TakeawaysModerna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion.The company expects much of its revenue to be realized in the back half of the year from its Covid-19 and RSV vaccines.Shares of Moderna have lost about two-thirds of their value over the past year and are well off their all-time high in August 2021. Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion. The company now projects revenue ...

Moderna's (MRNA -20.84%) sales are slowing down, and Moderna stock is going down -- a lot.The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025. Moderna in 2024...and 2025Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an "endemic" illness rather than a novel and spreading pandemic. CEO Sté ...

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates. The adjustment reflects weaker demand for its Covid-19 and RSV vaccines, with the company projecting that most of the revenue will materialize in the second half of the year.In response, MRNA was last seen 24% lower to trade at $32.11, at its lowest level since April 2020 -- before its pandemic-era surge -- and heading for its worst-ever single-day s ...

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates. The adjustment reflects weaker demand for its Covid-19 and RSV vaccines, with the company projecting that most of the revenue will materialize in the second half of the year.In response, MRNA was last seen 24% lower to trade at $32.11, at its lowest level since April 2020 -- before its pandemic-era surge -- and heading for its worst-ever single-day s ...

Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.The company will present at the 43rd Annual J.P. Morgan Healthcare Conference.In September, Moderna unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized p ...

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. The majority of those sales will come from Moderna's Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release.The guidance is down from a prior ...